CDEK
← All drugs Report issue

brentuximab vedotin

Trade name: adcetris

mAbapprovedADCOrphan Drug FDA

Approved

Aug 19, 2011

Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US. — Wikipedia

Clinical trial activity

181 trials · 128 clinical orgs · 1 marketing orgs

Phase 1
57
Phase 2
131
Phase 3
18
Phase 4
6

Earliest trial started Nov 1, 2006 (NCT00430846)

Timeline

2000s

  1. Jan 1, 2006

    Seattle Genetics — Earliest Phase 1 Sponsor(trial)

  2. Jan 30, 2007

    Orphan Drug Designation

  3. Jan 1, 2009

    Seattle Genetics — Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Seattle Genetics — Earliest Phase 3 Sponsor(trial)

  2. Aug 19, 2011

    Seattle Genetics — Earliest FDA Approval

  3. Aug 19, 2011

    Seattle Genetics — Marketing Organization

  4. Aug 19, 2011

    Seattle Genetics — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedAcceleratedAug 19, 2011

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No
Payload
Monomethylauristatin E

Oral

No

Parenteral

Yes

Topical

No

Black box warningFirst in class

Sources

Also known as

  • adcetris
  • adcetris
  • adcetris
  • adcetris
  • adcetris
  • brentuximab
  • brentuximab
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • brentuximab vedotin
  • bretuximab vedotin
  • cac10-1006
  • cac10-vcmmae
  • cac10-vcmmae
  • cac10-vcmmae
  • cac10-vcmmae
  • sgn-35
  • sgn-35
  • sgn-35
  • sgn-35

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07275216Phase 2Jul 1, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT07178457Phase 3Nov 1, 2025Assistance Publique - Hôpitaux de Paris
NCT06925555Phase 2Sep 30, 2025Nanjing Medical University
NCT07002216Phase 2Jul 15, 2025Pfizer, University of Miami
NCT07043283Phase 1Jul 1, 2025Akeso Pharmaceuticals, Inc.
NCT06761911Phase 4Dec 31, 2024Dalian Medical University
NCT06641388Phase 1Nov 4, 2024Akeso Pharmaceuticals, Inc.
NCT07074457N/ANov 1, 2024Soochow University
NCT06563245Phase 2/Phase 3 (Phase 3)Sep 25, 2024Anhui Medical University, Central South University, Children's Cancer Group, China, Hebei University, Huazhong University of Science and Technology, Jiao Tong University, Shandong University, Sichuan University, Sun Yat-Sen University, Tianjin Medical University, Tongji University, Zhengzhou University
NCT06563778Phase 2Sep 1, 2024People's Liberation Army of China
NCT06831370Phase 4Aug 28, 2024Takeda
NCT06393361Phase 2Jun 1, 2024People's Liberation Army of China
NCT06254495Phase 1May 28, 2024Seattle Genetics
NCT06377566Phase 2Apr 17, 2024Memorial Sloan-Kettering Cancer Center, Seattle Genetics
NCT06186986Phase 3Jan 31, 2024Takeda, University of Groningen
NCT06120504Phase 1Jan 31, 2024Seattle Genetics
NCT05922904Phase 2Dec 14, 2023Merck, Seattle Genetics, University of Texas at Houston
NCT05711628Phase 3Aug 10, 2023ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
NCT05675410Phase 3May 11, 2023National Cancer Institute (NCI), State University of New York, Buffalo
NCT07171827N/AMar 1, 2023Helwan University
Showing 20 of 181 trials
Page 1 / 10

Organizations

Research & Development (128)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Seattle GeneticsFor profit652852006
National Cancer Institute (NCI)Government28942011
Millennium PharmaceuticalsFor profit25752009
TakedaFor profit12442014
City of Hope National Medical CenterAcademic/Hospital10932011
University of Texas at HoustonAcademic/Hospital9822006
MerckFor profit6122016
Bristol-Myers SquibbFor profit5322012
Cornell UniversityAcademic/Hospital5332006
Fondazione Italiana Diabete OnlusAcademic/Hospital5512013
Harvard UniversityAcademic/Hospital5522012
The Lymphoma Academic Research OrganisationAcademic/Hospital5512015
University of WashingtonAcademic/Hospital5522012
New York Medical CollegeAcademic/Hospital4422014
The Lymphoma Study AssociationAcademic/Hospital4012015
University of BolognaAcademic/Hospital4012013
University of CologneAcademic/Hospital4422012
Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaAcademic/Hospital3312014
Northwestern UniversityAcademic/Hospital3312011
Stanford UniversityAcademic/Hospital3222011
128 organizations
Page 1 / 7

Marketing (2)

OrganizationOrg typeRelationshipDate
Seattle GeneticsFor profitMKTGAug 19, 2011
Seattle GeneticsFor profitNDAAug 19, 2011